China's Brain-Computer Interface Sector Achieves Multiple Breakthroughs, Establishing a Diversified Competitive Landscape

　　【Pharmaceutical Network Industry Dynamics】Some institutions have stated that brain-computer interface is expected to become the core technology of the next generation of human-computer interaction, changing the way humans interact with machines. It is reported that, with the continuous advancement of technology, there have been frequent new breakthroughs in China's brain-computer interface field recently.
 

On December 17, the Center for Excellence in Brain Science and Intelligence Technology of the Chinese Academy of Sciences announced new progress in the second invasive brain-computer interface clinical trial conducted in collaboration with domestic research institutions and medical units. This clinical trial achieved a significant technological shift from two-dimensional screen cursor control to three-dimensional interaction with the physical world.
 

On December 15, the National Medical Products Administration (NMPA) of China issued a Class III product registration certificate to SceneRay Co., Ltd. for its invasive brain-computer interface (BCI) system designed to treat drug addiction. This marks the world's first approved invasive BCI product for treating addiction-related mental disorders. The system stimulates the nucleus accumbens and anterior limb of the internal capsule, serving as an adjunctive therapy to prevent relapse in patients with refractory moderate to severe opioid addiction. The approval and market launch of this product signify a significant transition from research to commercialization in the field of invasive BCIs in China.
 

On December 13, NeuroXess announced that the first clinical trial of its self-developed fully implanted, fully wireless, and full-featured brain-computer interface product with a built-in battery was completed. All core modules of the product are completely implanted in the body, with no interfaces on the surface, utilizing wireless power supply and wireless data transmission more suitable for clinical applications. It enables real-time interaction without any external devices and represents another significant advancement in implantable hardware.
 

It is reported that brain-computer interface technology, which achieves "mind control" by collecting neural signals, has the value of functional substitution, remodeling, and enhancement. It is accelerating from concept verification into medical applications. Countries around the world are actively planning in this field, and China is also increasing policy support. For example, on November 25, the Ministry of Industry and Information Technology and five other departments issued a plan explicitly encouraging the development of intelligent terminals such as brain-computer interfaces.
 

Supported by favorable policies, China's brain-computer interface industry is moving from laboratories to clinical validation. In addition to the aforementioned progress, Zhejiang Shanxiahu Pearl Group Co., Ltd., as a key participant in the clinical transformation of invasive technologies, has drawn significant attention for the product line of its subsidiary, NeuroXess. The company’s exoskeleton system for upper limb rehabilitation has entered the multi-center clinical trial phase and is expected to complete the registration application for Class II medical devices by the first half of 2026.
 

Beijing Chieftain Control Engineering Technology Co., Ltd. stated on the interactive platform in September that the company has established a dual-track strategy of "invasive and non-invasive" approaches. In the field of non-invasive serious medical treatment, the company has released three rehabilitation device prototypes incorporating brain-computer interface technology. The registration application work is currently proceeding as planned. These products adopt a modular design, supporting multi-channel signal synchronous acquisition and closed-loop neuromodulation such as EEG (electroencephalogram), EMG (electromyography), and ECG (electrocardiogram). They possess precise coordination capabilities with electrical stimulation systems. Additionally, the devices support flexible expansion from 8 to 64 channels and feature low noise and wireless transmission. They are compatible with mainstream BCI and medical systems, providing highly reliable support for basic scientific research, neurorehabilitation, and brain-computer application development.
 

Industry insiders revealed that China's brain-computer interface (BCI) technology has made remarkable breakthroughs in core components and decoding algorithms. In terms of application scenarios, invasive BCIs are primarily focused on medical settings, with dozens of clinical cases already conducted. Non-invasive BCIs, on the other hand, are mainly deployed in consumer lifestyle and industrial fields, where multiple non-invasive devices have achieved mass production, gradually establishing a multi-scenario application ecosystem to pave the way for future large-scale commercialization. With the rapid development of BCI technology, China’s market has formed a diversified competitive landscape, with companies adopting different technological approaches positioning themselves across various application areas. Looking ahead, as technology continues to evolve and the ecosystem improves, BCIs will become a significant driving force for societal progress.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.